Requirement for Serratia marcescens cytolysin in a murine model of hemorrhagic pneumonia

Infection and Immunity

Volumn 83, Issue 2, 2015, Pages 614-624

  González Juarbe, Norberto ^a   Mares, Chris A ^a,b   Hinojosa, Cecilia A ^a   Medina, Jorge L ^a   Cantwell, Angelene ^a   Dube, Peter H ^a   Orihuela, Carlos J ^a   Bergman, Molly A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLYSIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BACTERIAL PROTEIN; CYTOKINE; HEMOLYSIN; SHLA PROTEIN, SERRATIA MARCESCENS; SHLB PROTEIN, SERRATIA MARCESCENS;

ACUTE DISEASE; AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPITHELIUM CELL; ERYTHROCYTE; FEMALE; FIBROBLAST; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; LUNG FUNCTION; LUNG HEMORRHAGE; LUNG HOMOGENATE; MACROPHAGE; MORBIDITY; MORTALITY; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NICK END LABELING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SERRATIA INFECTION; SERRATIA MARCESCENS; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLEEDING; BRONCHOALVEOLAR LAVAGE FLUID; CROSS INFECTION; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; LUNG; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PNEUMONIA;

ANIMALS; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CROSS INFECTION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HEMOLYSIN PROTEINS; HEMORRHAGE; INFLAMMATION; LUNG; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; NEUTROPHILS; PNEUMONIA; SERRATIA INFECTIONS; SERRATIA MARCESCENS;

EID: 84921415269     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01822-14     Document Type: Article

References (53)

1. Biedenbach DJ, Moet GJ, Jones RN. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from theSENTRYAntimicrobial SurveillanceProgram(1997-2002). Diagn Microbiol Infect Dis 50:59-69. http://dx.doi.org/10.1016/j.diagmicrobio.2004.05.003.
2. Grimont F, Grimont PAD. 2006. The genus Serratia. Prokaryotes 6:219-244. http://dx.doi.org/10.1007/0-387-30746-x_11.
3. Shih H, Lee H, Lee N. 2005. Serratia marcescens bacteremia at a medical center in southern Taiwan: high prevalence of cefotaxime resistance. J Microbiol Immunol Infect 38:350-357.
4. Jones RN. 2010. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(Suppl 1):S81-S87. http://dx.doi.org/10.1086/653053.
5. Su L, Ou J, Leu HS, Chiang PC, Chiu YP, Chia JH, Kuo AJ, Chiu CH, Chu C, Wu TL, Sun CF, Riley TV, Chang BJ. 2003. Extended epidemic of nosocomial urinary tract infections caused by Serratia marcescens. J Clin Microbiol 41:4726-4732. http://dx.doi.org/10.1128/JCM.41.10.4726-4732.2003.
6. Dessi A, Puddu M, Testa M. 2009. Serratia marcescens infections and outbreaks in neonatal intensive care units. J Chemother 5:493-499.
7. Laupland KB, Parkins MD, Gregson DB, Church DL, Ross T, Pitout JD. 2008. Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region. Eur J Clin Microbiol Infect Dis 27:89-95. http://dx.doi.org/10.1007/s10096-007-0400-7.
8. Goldstein F, Gutmann L. 1983. In vivo and in vitro emergence of simultaneous resistance to both x-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens. Ann Microbiol (Paris) 134A:329-337.
9. Liou B-H, Duh R-W, Lin Y-T, Yang Lauderdale T-L, Fung C-P. 2014. A multicenter surveillance of antimicrobial resistance in Serratia marcescens in Taiwan. J Microbiol Immunol Infect 47:387-93. http://dx.doi.org/10.1016/j.jmii.2013.04.003.
10. Kim SY, Shin J, Shin SY, Ko KS. 2013. Characteristics of carbapenemresistant Enterobacteriaceae isolates from Korea. Diagn Microbiol Infect Dis 76:486-490. http://dx.doi.org/10.1016/j.diagmicrobio.2013.04.006.
11. Lee HK, Park YJ, Kim JY, Chang E, Cho SG, Chae HS, Kang CS. 2005. Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases. Diagn Microbiol Infect Dis 52:331-336. http://dx.doi.org/10.1016/j.diagmicrobio.2005.04.012.
12. McKenna M. 2013. Antibiotic resistance: the last resort. Nature 499:394-396. http://dx.doi.org/10.1038/499394a.
13. Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy C-J, Steinbakk M, Winstanley TG, Kahlmeter G. 2013. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141-160. http://dx.doi.org/10.1111/j.1469-0691.2011.03703.x.
14. Balikian J, Herman P, Godleski J. 1980. Serratia pneumonia. Radiology 137:309-311. http://dx.doi.org/10.1148/radiology.137.2.7001538.
15. Bernard L, Sutton W. 1960. Infection due to chromobacteria. Report of a case of pneumonia due to Chromobacterium prodigiosum successfully treated with kanamycin. Arch Intern Med 105:159-163.
16. Goldstein JD, Godleski JJ, Balikian JP, Herman PG. 1982. Pathologic patterns of Serratia marcescens pneumonia. Hum Pathol 13:479-484. http://dx.doi.org/10.1016/S0046-8177(82)80031-2.
17. Meltz DJ, Grieco MH. 1973. Characteristics of Serratia marcescens pneumonia. Arch Intern Med 132:359-364. http://dx.doi.org/10.1001/archinte.132.3.359.
18. van der Vorm ER, Woldring-Zwaan C. 2002. Source, carriers, and management of a Serratia marcescens outbreak on a pulmonary unit. J Hosp Infect 52:263-267. http://dx.doi.org/10.1053/jhin.2002.1313.
19. Vogel JP, Andrews HL, Wong SK, Isberg RR. 1998. Conjugative transfer by the virulence system of Legionella pneumophila. Science 279:873-876. http://dx.doi.org/10.1126/science.279.5352.873.
20. Poole K, Braun V. 1988. Influence of growth temperature and lipopolysaccharide on hemolytic activity of Serratia marcescens. J Bacteriol 170: 5146-5152.
21. Könninger UW, Hobbie S, Benz R, Braun V. 1999. The haemolysinsecreting ShlB protein of the outer membrane of Serratia marcescens: determination of surface-exposed residues and formation of ionpermeable pores by ShlB mutants in artificial lipid bilayer membranes. Mol Microbiol 32:1212-1225. http://dx.doi.org/10.1046/j.1365-2958.1999.01433.x.
22. Boyd AR, Shivshankar P, Jiang S, Berton MT, Orihuela CJ. 2012. Age-related defects in TLR2 signaling diminish the cytokine response by alveolar macrophages during murine pneumococcal pneumonia. Exp Gerontol 47:507-518. http://dx.doi.org/10.1016/j.exger.2012.04.004.
23. Boyd AR, Hinojosa CA, Rodriguez PJ, Orihuela CJ. 2012. Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia. BMC Microbiol 12:73. http://dx.doi.org/10.1186/1471-2180-12-73.
24. Hertle R, Hilger M, Weingardt-Kocher S, Walev I. 1999. Cytotoxic action of Serratia marcescens hemolysin on human epithelial cells. Infect Immun 67:817-825.
25. Walker G, Hertle R, Braun V. 2004. Activation of Serratia marcescens hemolysin through a conformational change. Infect Immun 72:611-614. http://dx.doi.org/10.1128/IAI.72.1.611-614.2004.
26. Kurz Â, Chauvet S, Le C, Aurouze M, Vallet I, Bentzmann SD, Steinmetz I, Hoffmann JA, Finlay BB, Gorvel J-p, Ferrandon D, Ewbank JJ. 2003. Virulence factors of the human opportunistic pathogen Serratia marcescens identified by in vivo screening. EMBO J 22:1451-1460. http://dx.doi.org/10.1093/emboj/cdg159.
27. Yang FL, Braun V. 2000. ShlB mutants of Serratia marcescens allow uncoupling of activation and secretion of the ShlA hemolysin. Int J Med Microbiol 290:529-538. http://dx.doi.org/10.1016/S1438-4221(00)80018-1.
28. Zarogoulidis P, Porpodis K, Konoglou M, Saroglou M, Mitrakas A, Matthaios D, Touzopoulos P, Archontogeorgis K, Koulelidis A, Zarogoulidis K, Tryfon S. 2011. Serratia pneumonia presenting as hemoptysis in a patient with sarcoidosis: a case report. Int J Gen Med 4:661-664. http://dx.doi.org/10.2147/IJGM.S24706.
29. Shi C, Hohl TM, Leiner I, Equinda MJ, Fan X, Pamer EG. 2011. Ly6G neutrophils are dispensable for defense against systemic Listeria monocytogenes infection. J Immunol 187:5293-5298. http://dx.doi.org/10.4049/jimmunol.1101721.
30. Arnhold J. 2004. Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc) 69:4-9. http://dx.doi.org/10.1023/B:BIRY.0000016344.59411.ee.
31. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. 2010. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 191:677-691. http://dx.doi.org/10.1083/jcb.201006052.
32. Ben-David I, Price SE, Bortz DM, Greineder CF, Cohen SE, Bauer AL, Jackson TL, Younger JG. 2005. Dynamics of intrapulmonary bacterial growth in a murine model of repeated microaspiration. Am J Respir Cell Mol Biol 33:476-482. http://dx.doi.org/10.1165/rcmb.2005-0053OC.
33. Southern PM, Pierce AK, Sanford JP. 1971. Clearance of Serratia marcescens from lungs of normal mice. Infect Immun 3:187-188.
34. Lyerly DM, Kreger AS. 1983. Importance of Serratia protease in the pathogenesis of experimental Serratia marcescens pneumonia. Infect Immun 40:113-119.
35. Pociask DA, Scheller EV, Mandalapu S, McHugh KJ, Enelow RI, Fattman CL, Kolls JK, Alcorn JF. 2013. IL-22 is essential for lung epithelial repair following influenza infection. Am J Pathol 182:1286-1296. http://dx.doi.org/10.1016/j.ajpath.2012.12.007.
36. Price JF. 1990. Acute and long-term effects of viral bronchiolitis in infancy. Lung 168(Suppl):414-421. http://dx.doi.org/10.1007/BF02718159.
37. Mizgerd JP, Lupa MM, Hjoberg J, Vallone JC, Warren HB, Butler JP, Silverman ES. 2004. Roles for early response cytokines during Escherichia coli pneumonia revealed by mice with combined deficiencies of all signaling receptors for TNF and IL-1. Am J Physiol Lung Cell Mol Physiol 286:L1302-L1310. http://dx.doi.org/10.1152/ajplung.00353.2003.
38. Russo Ta, Bartholomew La, Davidson Ba, Helinski JD, Carlino UB, Knight PR, Beers MF, Atochina EN, Notter RH, Holm Ba. 2002. Total extracellular surfactant is increased but abnormal in a rat model of gramnegative bacterial pneumonia. Am J Physiol Lung Cell Mol Physiol 283: L655-L663.
39. Ioachimescu O, Stoller J. 2008. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleveland Clin J Med 75:258-280. http://dx.doi.org/10.3949/ccjm.75.4.258.
40. Yousem SA. 1993. Immunologic lung disease: immune alveolar hemorrhage and lung allograft rejection. Monogr Pathol 36:93-133.
41. Gibson RL, Nizet V, Rubens CE. 1999. Group B streptococcal betahemolysin promotes injury of lung microvascular endothelial cells. Pediatr Res 45:626-634. http://dx.doi.org/10.1203/00006450-199905010-00003.
42. Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M, Rubens CE. 1996. Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells. Infect Immun 64:3818-3826.
43. Johnson JS, Croall J, Power JS, Armstrong GR. 1998. Fatal Serratia marcescens meningitis and myocarditis in a patient with an indwelling urinary catheter. J Clin Pathol 51:789-790. http://dx.doi.org/10.1136/jcp.51.10.789.
44. Maragakis LL, Winkler A, Tucker MG, Cosgrove SE, Ross T, Lawson E, Carroll KC, Perl TM. 2008. Outbreak of multidrug-resistant Serratia marcescens infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol 29:418-423. http://dx.doi.org/10.1086/587969.
45. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. 1989. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 114:555-560. http://dx.doi.org/10.1016/S0022-3476(89)80693-6.
46. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. 2012. Neutro-phil function: from mechanisms to disease. Annu Rev Immunol 30:459-489. http://dx.doi.org/10.1146/annurev-immunol-020711-074942.
47. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. 2004. Neutrophil extracellular traps kill bacteria. Science 303:1532-1535. http://dx.doi.org/10.1126/science.1092385.
48. Aulik NA, Hellenbrand KM, Klos H, Czuprynski CJ. 2010. Mannheimia haemolytica and its leukotoxin cause neutrophil extracellular trap formation by bovine neutrophils. Infect Immun 78:4454-4466. http://dx.doi.org/10.1128/IAI.00840-10.
49. Gordon SB, Read RC. 2002. Macrophage defences against respiratory tract infections. Br Med Bull 61:45-61. http://dx.doi.org/10.1093/bmb/61.1.45.
50. Thoma-Uszynski S, Stenger S, Takeuchi O. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291:1544-1154. http://dx.doi.org/10.1126/science.291.5508.1544.
51. Choi aM, Jacoby DB. 1992. Influenza virus A infection induces interleukin-8 gene expression in human airway epithelial cells. FEBS Lett 309:327-329. http://dx.doi.org/10.1016/0014-5793(92)80799-M.
52. Clemans D, Bauer R. 2000. Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzae. Infect Immun 68:4430-4440. http://dx.doi.org/10.1128/IAI.68.8.4430-4440.2000.
53. Cooksey RC, Bannister ER, Farrar WE, Jr. 1975. Antibiotic resistance patterns of clinical isolates of Serratia marcescens. Antimicrob Agents Chemother 7:396-399. http://dx.doi.org/10.1128/AAC.7.4.396.